VCL

Across TCGA pan-cancer cohorts, VCL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VCL data layer compared with 31 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher VCL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VCL expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

UCEC, CCRCC, and PDAC are the cancer types where VCL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.433	1.000	.007	12	view →
CCRCC	OS	Tertile	IV	0.198	0.830	.024	12	view →
PDAC	DFS	Quartile	II,III,IV	0.613	0.309	.007	10	view →
LSCC	DFS	Median	II,III,IV	0.836	1.000	.005	7	view →
LUAD	DFS	Tertile	II,III,IV	0.696	0.973	.007	5	view →
GBM	OS	Quartile	All	0.677	0.959	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VCL–UCEC (OS)

Open the UCEC breakdown →